Neuren Pharmaceuticals Ltd (NEU) — Cash Flow Quality Index
Neuren Pharmaceuticals Ltd (NEU) has a Cash Flow Quality Index of 8.54x as of June 2025. Operating cash flow of AU$128.31 Million exceeds net income of AU$15.03 Million, indicating high earnings quality where cash backs reported profits. Explore NEU cash flow conversion to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Neuren Pharmaceuticals Ltd Cash Flow Quality Index (2009–2024)
Historical Cash Flow Quality Index for Neuren Pharmaceuticals Ltd across 6 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Neuren Pharmaceuticals Ltd investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Neuren Pharmaceuticals Ltd (2009–2024)
Year-by-year earnings quality comparison for Neuren Pharmaceuticals Ltd. For live market cap and the full company financial profile, see NEU stock market capitalisation.
| Year | Quality Index | Operating CF (AUD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | -0.08x | AU$-11.27 Million | AU$142.04 Million | ▼ -106.7% |
| 2023 | 1.18x | AU$184.93 Million | AU$157.08 Million | ▼ -94.0% |
| 2022 | 19.56x | AU$3.60 Million | AU$184.00K | ▲ +838.0% |
| 2018 | 2.09x | AU$6.41 Million | AU$3.07 Million | ▲ +222.7% |
| 2017 | -1.70x | AU$-5.59 Million | AU$3.29 Million | ▲ +86.8% |
| 2009 | -12.93x | AU$-1.29 Million | AU$99.56K | — |